Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 760-762

  Itzykson, Raphael ^a   Fenaux, Pierre ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ASXL1 PROTEIN; AZACITIDINE; CYTARABINE; DNA METHYLTRANSFERASE 3A; HEMATOLOGIC AGENT; HYPOMETHYLATING AGENT; PROTEIN; TET2 PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

DNA METHYLATION; DRUG RESPONSE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; NOTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS; SCORING SYSTEM;

AZACITIDINE; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 84859935049     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.651618     Document Type: Note

References (25)

1. F enaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Effi cacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232.
2. L ubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: fi nal results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011;29:1987-1996.
3. Fenaux P, Gattermann N, Seymour JF, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol 2010;149: 244-249.
4. Itzykson R, Th epot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117:403-411.
5. L ist AF, Fenaux P, Mufti GJ, et al. Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. J Clin Oncol 2008;26(15 Suppl.) Abstract 7006.
6. Moon JH, Kim SN, Kang BW, et al. Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment. Ann Hematol 2010;89:681-689.
7. Wijermans PW, Lubbert M, Verhoef G, et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2́ -deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005;84(Suppl. 1):9-17.
8. Kantarjian HM, O'Brien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007;109: 265-273. (Pubitemid 46106241)
9. Breccia M, Loglisci G, Cannella L, et al. Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to evaluate overall survival and rate of response. Leuk Lymphoma 2012;53:982-983.
10. v an der Helm LH, Alhan C, Wijermans PW, et al. Platelet doubling after the fi rst azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol 2011;155:599-606.
11. Koreth J, Pidala J, Perez WS, et al. A decision analysis of reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation for older patients with de-novo myelodysplastic syndrome (MDS): early transplantation off ers survival benefi t in higher-risk MDS. Blood 2011;118(Suppl. 1): Abstract 115.
12. Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011;29:3322-3327.
13. S anna A, Cannella L, Gozzini A, et al. Comorbidities indexes in patients treated with 5-azacitidine are a an useful and easily applicable tool to refine prognostic evaluation. Blood 2010;116 (Suppl. 1): Abstract 606.
14. F andy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009;114:2764-2773.
15. K antarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-57. (Pubitemid 46053042)
16. S hen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010;28:605-613.
17. B lum W, Garzon R, Klisovic RB, et al. Clinical response and miR- 29b predictive signifi cance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010;107:7473-7478.
18. B raun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase II trial. Blood 2011;118:3824-3831.
19. F ollo MY, Finelli C, Mongiorgi S, et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci USA 2009;106:16811-16816.
20. Tiu RV, Visconte V, Traina F, et al. Updates in cytogenetics and molecular markers in MDS. Curr Hematol Malig Rep 2011;6:126-135.
21. F igueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic diff erentiation. Cancer Cell 2010;18:553-567.
22. Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011;25:1147-1152.
23. T raina F, Jankowska AM, Visconte V, et al. Impact of molecular mutations on treatment response to hypomethylating agents in MDS. Blood 2011;118(Suppl. 1): Abstract 461.
24. W alker AR, Metzeler KH, Geyer S, et al. Impact of DNMT3A mutations on clinical response to the hypomethylating agent decitabine in older patients (pts) with acute myeloid leukemia (AML). Blood 2011;18(Suppl. 1): Abstract 944.
25. Grossmann V, Kohlmann A, Eder C, et al. Analyses of 81 chronic myelomonocytic leukemia (CMML) for EZH2, TET2, ASXL1, CBL, KRAS, NRAS, RUNX1, IDH1, IDH2, and NPM1 revealed mutations in 86.4% of all patients with TET2 and EZH2 being of high prognostic relevance. Blood 2010;116(Suppl. 1): Abstract 296.